Some common lipotropics include vitamin B12, vitamin B6, methionine, inositol, and choline
In clinical studies, only 1.5% of people using the lower dose and 0.4% using the higher dose developed gallstones
For full clinical data, see our GLP-1 weight loss guide
Mt nh gi c rt ra t 30 nghin cu vi hn 80.000 ngi tham gia cho thy b sung axit folic gip gim 10% nguy c t qu v 4% nguy c mc bnh tim tng th
Cognitive Function Some research suggests growth hormone may support brain health and cognitive function, including memory and focus
Conclusion (Summary first) GLP-1 receptor agonists may increase the risk of cholelithiasis and gallbladder disease The risk is tending to be higher with drugs and dosages that cause greater weight loss The mechanism is reduced gallbladder motility + rapid weight loss Cholelithiasis risk: Overall picture In large-scale meta-analyses, GLP-1 receptor agonist use Gallbladder disease risk: RR 1.37 Cholelithiasis: RR 1.27 Cholecystitis: RR 1.36 1) It is important to note that while this is a significant increase, the "absolute risk is not high." Differences in risk by drug Liraglutide (Victoza) The increase in cholelithiasis risk is relatively clear In the SCALE trials, Gallstone-related events: 2.3% vs 1.0% (placebo) 2) Increased in the group with greater weight loss Semaglutide (Ozempic/Wegovy) In the STEP trials, etc., Gallbladder disease increasing trend (approx
